{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-24-000037","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2024-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.167230+00:00","generated_at":"2026-06-01T08:43:33.233053+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Elicio reports preliminary Phase 1a data for ELI-002 7P: 100% T cell response, biomarker reductions","bullets":["ELI-002 7P generated mKRAS-specific T cell response in 100% (11/11) evaluable patients; responses against all mutations enrolled.","At 4.9 mg RP2D, 66.7% (4/6) had both CD8+ and CD4+ responses; biomarker reductions in 71% (5/7) evaluable patients.","Antigen-spreading observed: T cell responses targeting non-immunizing tumor neoantigens in 100% (6/6) at RP2D.","No dose-limiting toxicities, no treatment-related serious adverse events or cytokine release syndrome.","Recommended Phase 2 dose: 4.9 mg AMP-Peptides 7P with 10 mg AMP-CpG-7909."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-24-000037","json":"https://secwatch.observer/filing/0001601485-24-000037.json","markdown":"https://secwatch.observer/filing/0001601485-24-000037.md","text":"https://secwatch.observer/filing/0001601485-24-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000037/0001601485-24-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148524000037/angn-20240523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:43:33.233053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}